The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert - The Danish firm blamed the move to slash its ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk submitted the 7.2 mg dose of Wegovy to offer a tailored option for people with obesity who need greater weight loss support.

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. The GLP-1 obesity med soared to the top of the month’s ranking of TV drug ad spenders ...